Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
NCT00022347Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2001
- Primary completion
- Apr 2004
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canfosfamide in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Objective Response Rate, Disease Stabilization Rate and 4 more. Started May 2001; status: completed.
02
Drugs
canfosfamide
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00022347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022347.